114 related articles for article (PubMed ID: 18199534)
1. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma.
Shen Z; Yang ZF; Gao Y; Li JC; Chen HX; Liu CC; Poon RT; Fan ST; Luk JM; Sze KH; Li TP; Gan RB; He ML; Kung HF; Lin MC
Cancer Res; 2008 Jan; 68(2):404-14. PubMed ID: 18199534
[TBL] [Abstract][Full Text] [Related]
2. A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma.
Shen Z; Wong OG; Yao RY; Liang J; Kung HF; Lin MC
Cancer Lett; 2008 Dec; 272(2):268-76. PubMed ID: 18722051
[TBL] [Abstract][Full Text] [Related]
3. Overexpressing kringle 1 domain of hepatocyte growth factor with adeno-associated virus inhibits the pathological retinal neovascularization in an oxygen-induced retinopathy mouse model.
Sun P; Liu Z
Biochem Biophys Res Commun; 2019 Jan; 508(1):130-137. PubMed ID: 30471863
[TBL] [Abstract][Full Text] [Related]
4. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
5. AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer.
Nie B; Shen Z; Wen JB; Wong OG; Hsueh WD; Huo LF; Kung HF; Jiang B; Lin MC
Mol Cancer Ther; 2008 Sep; 7(9):2855-65. PubMed ID: 18790766
[TBL] [Abstract][Full Text] [Related]
6. A novel and effective human hepatocyte growth factor kringle 1 domain inhibits ocular neovascularization.
Lu Q; Zhang L; Shen X; Zhu Y; Zhang Q; Zhou Q; Gan R; Zhang H; Zhong Y; Xie B
Exp Eye Res; 2012 Dec; 105():15-20. PubMed ID: 23085338
[TBL] [Abstract][Full Text] [Related]
7. Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis.
Shen Z; Yao C; Wang Z; Yue L; Fang Z; Yao H; Lin F; Zhao H; Sun YJ; Bian XW; Jiang W; Wang X; Li Y; Lu G; Poon WS; Kung HF; Lin MC
Mol Ther; 2016 Aug; 24(8):1358-68. PubMed ID: 26961408
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice.
Lee K; Yun ST; Kim YG; Yoon Y; Jo EC
Hepatology; 2006 May; 43(5):1063-73. PubMed ID: 16628632
[TBL] [Abstract][Full Text] [Related]
9. HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases.
Zhou XH; Tang LN; Yue L; Min DL; Yang Y; Huang JA; Shen Z
Asian Pac J Cancer Prev; 2012; 13(4):1457-61. PubMed ID: 22799348
[TBL] [Abstract][Full Text] [Related]
10. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
Gao X; Jiang P; Zhang Q; Liu Q; Jiang S; Liu L; Guo M; Cheng Q; Zheng J; Yao H
J Exp Clin Cancer Res; 2019 Aug; 38(1):362. PubMed ID: 31426831
[TBL] [Abstract][Full Text] [Related]
11. Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma.
Torimura T; Ueno T; Kin M; Taniguchi E; Nakamura T; Inoue K; Sakata R; Hashimoto O; Sakamoto M; Ohira H; Kumashiro R; Sata M; Yano H; Kojiro M; Veitonmaki N; Cao Y
Gastroenterology; 2006 Apr; 130(4):1301-10. PubMed ID: 16618420
[TBL] [Abstract][Full Text] [Related]
12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
13. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis.
Xin L; Xu R; Zhang Q; Li TP; Gan RB
Biochem Biophys Res Commun; 2000 Oct; 277(1):186-90. PubMed ID: 11027661
[TBL] [Abstract][Full Text] [Related]
14. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
15. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Hu J; Dong A; Fernandez-Ruiz V; Shan J; Kawa M; MartÃnez-Ansó E; Prieto J; Qian C
Cancer Res; 2009 Sep; 69(17):6951-9. PubMed ID: 19690140
[TBL] [Abstract][Full Text] [Related]
16. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
[TBL] [Abstract][Full Text] [Related]
18. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
19. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
20. H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma.
Zhang W; Duan R; Zhang J; Cheung WKC; Gao X; Zhang R; Zhang Q; Wei M; Wang G; Zhang Q; Mei PJ; Chen HL; Kung H; Lin MC; Shen Z; Zheng J; Zhang L; Yao H
Br J Cancer; 2018 Feb; 118(4):522-533. PubMed ID: 29348487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
